Dyne Therapeutics (NASDAQ:DYN) Raised to “Sell” at Wall Street Zen

Dyne Therapeutics (NASDAQ:DYN) was upgraded by equities researchers at Wall Street Zen from a “strong sell” rating to a “sell” rating in a note issued to investors on Saturday.

Other equities analysts have also recently issued research reports about the stock. Jefferies Financial Group reaffirmed a “buy” rating on shares of Dyne Therapeutics in a research report on Monday, March 9th. Weiss Ratings reissued a “sell (d-)” rating on shares of Dyne Therapeutics in a research report on Monday, April 20th. HC Wainwright decreased their price target on Dyne Therapeutics from $60.00 to $50.00 and set a “buy” rating on the stock in a research note on Tuesday, March 3rd. Sanford C. Bernstein raised their price target on Dyne Therapeutics from $23.00 to $24.00 and gave the stock a “market perform” rating in a research report on Wednesday, May 13th. Finally, Chardan Capital reaffirmed a “buy” rating and issued a $38.00 price objective on shares of Dyne Therapeutics in a research note on Monday, March 9th. Three research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $33.85.

Dyne Therapeutics Stock Performance

Shares of DYN stock opened at $19.80 on Friday. The company has a debt-to-equity ratio of 0.17, a current ratio of 19.92 and a quick ratio of 19.92. The firm has a market cap of $3.27 billion, a PE ratio of -6.15 and a beta of 1.09. The company has a 50-day moving average of $18.33 and a two-hundred day moving average of $18.10. Dyne Therapeutics has a 1-year low of $8.06 and a 1-year high of $25.00.

Dyne Therapeutics (NASDAQ:DYN) last announced its quarterly earnings results on Monday, May 11th. The company reported ($0.73) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.77) by $0.04. During the same quarter last year, the firm earned ($1.05) EPS. On average, analysts predict that Dyne Therapeutics will post -3 EPS for the current year.

Insider Activity at Dyne Therapeutics

In related news, Director Jason P. Rhodes sold 287,956 shares of Dyne Therapeutics stock in a transaction that occurred on Wednesday, April 22nd. The shares were sold at an average price of $19.68, for a total value of $5,666,974.08. Following the completion of the transaction, the director owned 11,663 shares in the company, valued at approximately $229,527.84. The trade was a 96.11% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have purchased 9,000 shares of company stock valued at $156,800 and have sold 1,559,462 shares valued at $29,814,746. Insiders own 9.46% of the company’s stock.

Institutional Investors Weigh In On Dyne Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the business. Hilton Head Capital Partners LLC acquired a new position in shares of Dyne Therapeutics in the first quarter worth $26,000. Strs Ohio purchased a new stake in shares of Dyne Therapeutics during the fourth quarter worth $51,000. Aster Capital Management DIFC Ltd acquired a new stake in shares of Dyne Therapeutics in the fourth quarter valued at $84,000. Steward Partners Investment Advisory LLC raised its stake in shares of Dyne Therapeutics by 102.1% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 4,880 shares of the company’s stock valued at $95,000 after acquiring an additional 2,465 shares in the last quarter. Finally, Tower Research Capital LLC TRC boosted its holdings in Dyne Therapeutics by 275.1% in the second quarter. Tower Research Capital LLC TRC now owns 10,495 shares of the company’s stock valued at $100,000 after purchasing an additional 7,697 shares during the period. 96.68% of the stock is currently owned by institutional investors and hedge funds.

Dyne Therapeutics Company Profile

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.